Arecor Therapeutics

FY23 results evidence broader revenue base

Lighthouse | 16 May 2024

Share this note

  • Arecor FY23 revenues of £4.6m (+90% on FY22: £2.4m), as disclosed in the Trading Update (February 2024 Lighthouse), included first recurring royalties on AT220 and the EU launch associated milestone. The bulk of revenues came from Tetris Pharma sales of £2.9m, largely from Ogluo (FY22: £1.1m for five months post the August acquisition), in addition to £0.9m (FY22: £1.4m) of revenue recognised under ongoing formulation development projects, and £0.7m from license milestones. Total income of £5.7m (FY22: £3.7m) includes the Innovate UK grant and RDEC income.
  • Lower R&D spend of £6.0m in FY23 (FY22: £8.6m) reflected the timing of AT247 and AT278 clinical studies, while SG&A costs rose to £8.9m (FY22: £5.6m) as they included a full year of Tetris expenses vs five months in FY22. Net loss for the year was £8.6m (FY22: loss of £9.3m). Cash at end-December 2023 was £6.8m (end-June: £8.2m; end-December 2022: £12.8m). Cash needs will be determined by future development plans for the diabetes franchise, which will depend on upcoming data.
  • Several key events were achieved in 2023 with partnered/licenced assets, most notably the launch of AT220 in Europe in late-2023, the first commercial product incorporating the Arestat technology. AT220 is believed to be Fresenius Kabi’s tocilizumab (Tyenne); we note that US approval of Tyenne (both IV and subcutaneous) was received on 5 March 2024, with launch on 15 April. FY23 milestones were also received from Hikma (AT307) and Inhibrx (INBRX-101). Acquisition of the latter, by Sanofi for >$1.7bn (January 2024 Lighthouse), provides external validation of the value-add of Arecor’s formulation expertise.
  • Arecor’s formulation expertise underpins the six new technology partnerships executed in FY23 and post-period, including with Medtronic for a thermostable insulin (May 2024 Lighthouse). In addition, Arecor established a co-development research collaboration with TRx Biosciences to develop an oral GLP-1 (March 2024 Lighthouse). Collaborations are a key aspect of Arecor’s strategy, often generating revenues from day one via research fees, with upside potential should they convert to licences.

Trinity Delta view: Arecor’s revenue base is becoming increasingly diverse with growing contributions from Tetris Pharma product sales and nascent recurring royalties from the first approved Arestat-enabled product, on top of licence milestones and revenues under formulation development contracts. Continued deal execution has the potential to drive meaningful future royalties from multiple partners, building on the continued momentum from existing assets and partners. Topline data in H124 from the AT278 Phase I trial in Type II diabetes patients is an important catalyst, informing next steps for development and partnering/collaboration strategy. This disruptor insulin, which has the potential to address key unmet needs in diabetes, is one asset in the in-house portfolio of Diabetes and Specialty Hospital products, which together have significant upside potential. Our valuation is £179m, equivalent to 583p per share.

Lighthouse

16 May 2024

Price136.5p
Market Cap£41.8m
Primary exchangeAIM London
SectorHealthcare
Company CodeAREC
Corporate clientYes

Company description

Arecor Therapeutics is a revenue-generating clinical stage drug developer, with a well-balanced portfolio of in-house and partnered programmes. Its proprietary Arestat formulation platform results in enhanced products with lower development risks and less onerous regulatory approvals.

Analysts

Lala Gregorek
lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner
pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Disclaimer

Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.